Literature DB >> 11006135

Antisense therapy in cancer.

W Pawlak1, J Zolnierek, T Sarosiek, C Szczylik.   

Abstract

This review discusses laboratory and clinical studies of antisense oligodeoxynucleotides as potential treatments for haematological malignancies and solid tumours. Mechanisms of action, pharmacokinetics, toxicities and potential clinical applications of these agents are described. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11006135     DOI： 10.1053/ctrv.2000.0173

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  4 in total

1.  Metal-bipyridine complexes in DNA backbones and effects on thermal stability.

Authors:  Mildred M Rodriguez-Ramos; Jonathan J Wilker
Journal:  J Biol Inorg Chem       Date:  2010-02-26       Impact factor: 3.358

2.  A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells.

Authors:  Z Su ; I V Lebedeva; R V Gopalkrishnan; N I Goldstein; C A Stein; J C Reed; P Dent; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

3.  Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice.

Authors:  Caroline A Lamb; Luisa A Helguero; Sebastián Giulianelli; Rocío Soldati; Silvia I Vanzulli; Alfredo Molinolo; Claudia Lanari
Journal:  Breast Cancer Res       Date:  2005-11-09       Impact factor: 6.466

4.  Condensation of oligonucleotides assembled into nicked and gapped duplexes: potential structures for oligonucleotide delivery.

Authors:  Tumpa Sarkar; Christine C Conwell; Lilia C Harvey; Catherine T Santai; Nicholas V Hud
Journal:  Nucleic Acids Res       Date:  2005-01-07       Impact factor: 16.971
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.